Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Danish drugmaker Novo Nordisk has partnered Emcure Pharmaceuticals to commercialise Poviztra, a 2.4 milligram (mg) semaglutide injection marketed as a second brand of the weight-loss drug Wegovy in India.

 

Under the agreement, Emcure will exclusively distribute and market Poviztra in the country, becoming the first Indian company to secure sole distribution rights for a semaglutide injection.

 

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist and the active ingredient in Wegovy, is administered once a week through a pre-filled injection pen. It is approved as an adjunct to diet and exercise for chronic weight management and also helps lower the risk of